Amplia Therapeutics Limited

Equities

ATX

AU0000023822

Biotechnology & Medical Research

Market Closed - Australian S.E. 12:57:22 2024-03-28 am EDT 5-day change 1st Jan Change
0.077 AUD 0.00% Intraday chart for Amplia Therapeutics Limited 0.00% -3.75%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Amplia Concludes Phase I Trials of Anti-Cancer Drug; Prepares for Phase II MT
Amplia Therapeutics Updates on Pancreatic Cancer Trial; Phase-Two Recruitment Ongoing; Shares Up 3% MT
Amplia Therapeutics Secures US FDA Clearance for Proposed Pancreatic Cancer Trial MT
Amplia Therapeutics Limited Announces FDA Clearance of it's IND for Pancreatic Cancer Trial in US CI
Amplia Therapeutics Doses First Patient in Phase 2A Pancreatic Cancer Trial MT
Amplia Therapeutics Secures South Korean Regulatory Approval for Pancreatic Cancer Trial; Shares Up 3% MT
Amplia Therapeutics Limited Reports Earnings Results for the Half Year Ended September 30, 2023 CI
Amplia Therapeutics Receives AU$2.4 Million R&D Tax Rebate MT
Amplia Therapeutics Appoints CFO MT
Amplia Therapeutics Limited Announces Chief Financial Officer Changes CI
Amplia Therapeutics Gets Nod to Name Drug AMP945 Narmafotinib MT
Amplia Therapeutics Limited Reports Earnings Results for the Full Year Ended March 31, 2023 CI
Amplia Therapeutics Limited Auditor Raises 'Going Concern' Doubt CI
Amplia Therapeutics to Enter Research Collaboration with CSIRO; Shares Rise 7% MT
Amplia Receives Grant to Collaborate with CSIRO CI
Amplia Therapeutics Advances Clinical Trial for Pancreatic Cancer Inhibitor Drug MT
Amplia Therapeutics Doses First Patient for Third Cohort of Pancreatic Cancer Trial; Shares Rise 6% MT
Amplia Therapeutics Secures Clearance for Third Dose Cohort of Pancreatic Cancer Trial MT
Amplia Therapeutics Limited Announces Completion of Enrolment of the Second Cohort of Patients in the Ongoing Phase 1b/2a ACCENT Clinical Trial in Frontline Patients with Pancreatic Cancer CI
Amplia Therapeutics Limited Announces First Patient Recruited to Cohort 2 of Accent Trial in Pancreatic Cancer CI
Amplia Therapeutics Secures Approval for Dose Escalation Stage of Pancreatic Cancer Trial MT
Amplia Therapeutics Limited Announces Dose Escalation Approved in ACCENT Clinical Trial of AMP945 CI
Amplia Therapeutics Enrols First Set of Patients in Clinical Trial of Pancreatic Cancer Treatment MT
Amplia Therapeutics Limited Reports Earnings Results for the Half Year Ended September 30, 2022 CI
Amplia Therapeutics Appoints Managing Director and CEO MT
Chart Amplia Therapeutics Limited
More charts
Amplia Therapeutics Limited is an Australia-based clinical-stage, drug development company. The Company is focused on developing proprietary, orally available, small molecule Focal Adhesion Kinase (FAK) inhibitors as candidate drugs for the treatment of cancer and various fibrotic diseases. The Company's pipeline includes AMP945 and AMP886. AMP945 is a selective and potent inhibitor of FAK and is in clinical development for pancreatic cancer and advanced preclinical development for idiopathic pulmonary fibrosis (IPF). The Company's second pipeline drug, AMP886, inhibits FAK and inhibits two key disease drug targets (VEGFR3 and FLT3). This drug is being evaluated in preclinical models of cancer. Its fibrosis program uses its FAK inhibitors to block fibrosis and cell migration in cancers. Its cancer Program is directed at using its FAK inhibitors to block FAK activity in the cancer cells and the surrounding tissue and therefore block survival/proliferation signals.
More about the company
  1. Stock
  2. Equities
  3. Stock Amplia Therapeutics Limited - Australian S.E.
  4. News Amplia Therapeutics Limited
  5. Amplia Therapeutics Recruits First Patient for Pancreatic Cancer Clinical Trial